Business Wire

Mavenir Proves AMD Technology across its Open RAN OpenBeam™ Radio and Converged Packet Core Portfolio

Share

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud, today announced new initiatives in collaboration with AMD to help Communication Service Providers (CSPs) in their transition to cloud-native telecommunication networks.

First, Mavenir and AMD have been collaborating in Open RAN to build industry leading radio technology. Mavenir has incorporated the AMD Zynq™ Ultrascale+™ RFSoC devices into Mavenir’s OpenBeam™ Radio Portfolio and, through this partnership, both companies continue to work together to introduce new functionality, features, and capabilities to customers.

Secondly, Mavenir’s Converged Packet Core has been validated on AMD EPYC™ CPUs – This means Mavenir’s cloud-native, fully containerized, virtualized Converged Packet Core (4G & 5G) solution can now be deployed on AMD EPYC server CPUs to provide CSPs with more options to implement virtual network functions in cloud data centers.

The elements validated include AMF, SMF, UPF, UDSF, NRF, NSSF, AUSF, UDM, and UDR network functions. Additionally, PCF, NEF, BSF, MME, SecGw, PCRF, MME and SGSN network functions will be validated in the coming months.

“Mavenir’s commitment to enabling networks built on software that runs on any cloud revolves around giving CSPs the ability to use the best components that fit their specific needs, in the cell-site and in the data center,” said Bejoy Pankajakshan, EVP, Chief Technology and Strategy Officer, Mavenir. “Mavenir and AMD are working together to give CSPs multiple options and help them optimize power consumption, network efficiency and total cost of ownership in the radio access as well as the core network.”

“Cloud-native telecom networks empower CSPs with systems that offer flexibility, lower operational cost, ease of system management, and a broader ecosystem for value add, innovation, and upgrade capabilities as network requirements grow,” said Salil Raje, senior vice president and general manager, Data Center and Communications Group, AMD. “We are extremely proud of our close collaboration with Mavenir to help deliver exceptional TCO and predictable scalability along with high performance and power efficient solutions to telecommunications operators leveraging AMD data center products.”

Mavenir’s OpenBeam innovative radio portfolio is specifically designed for the growing needs of CSPs with agile, cost-efficient, intelligent radios to meet critical demands on the network now, and as the network changes and expands. The radio solutions can be used for a wide range of use cases, including basic coverage across all frequency bands, outdoor small cells, for public and private networks providing business and consumer services in both urban and rural environments.

Mavenir’s Converged Packet Core is an end-to-end, fully containerized portfolio that offers multi-generational support to modernize existing mobile networks while providing a cost-effective journey to 5G. Its cloud-native architecture, with applications and services purpose-built for the cloud model, offers easy scaling, hardware decoupling, agility, portability and resiliency across public, private and hybrid clouds. Its web-scale granular microservice architecture meets carrier-grade requirements such as high availability, security, and performance.

To know more about the joint collaboration, visit Mavenir (hall 2 stand 2H60) and AMD (hall 2 stand 2M61) at Mobile World Congress 2023 in Barcelona (February 27th – March 2nd).

AMD, the AMD Arrow logo, EPYC™, Zynq™ and Ultrascale+™, and combinations thereof, are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world's subscribers. www.mavenir.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR Contact:
PR@mavenir.com

Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye